|
Endocrinologic and Metabolic Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID, NICHD
|
This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval.
|
|
Enhanced Federal Collaborations in Implementation Science and Research of HIV Prevention and Treatment
|
Other
|
CDC, HRSA
|
NIAID, NIMH
|
This paper describes federal collaborations that have supported this increased focus on implementation from the perspective of NIH, CDC, and HRSA, resulting in improved communication and coordination of efforts in the shaping and alignment of priorities in research and service delivery, increased implementation research conducted in real-world community and clinical settings.
|
|
Enhancing Scientific Collaboration between US and Colombia
|
Committee, Work group, Advisory group, or Task Force
|
OGA
|
NIA, NIAID, FIC
|
The Office of the Americas of the HHS has formed a group consisting of representatives from NIAID, FIC, and NIA to foster communication with the goal of enhancing scientific collaboration between US and Colombia.
|
|
Environmental Phthalate Exposures In Pregnancy in Relation to Fetal and Placental Development
|
Research Initiative
|
CDC
|
NIEHS
|
The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development.
|
|
Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemic
|
Research Initiative
|
FDA
|
NIAID
|
Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemic
|
|
eRA Federal Shared Services (eRA)
|
Resource Development
|
AHRQ, FDA, SAMHSA, ASFR
|
OD/OER
|
Grants Quality Service Management Office (Grants QSMO) Marketplace solution provider. Collaboration with other HHS agencies and federal agencies to provide electronic Research Administration (eRA) grants management services and support across the full grants life cycle.
|
|
Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures
|
Research Initiative
|
FDA
|
NCI
|
NCI and FDA investigators are collaborating to establish representative examination and organ doses for fluoroscopically-guided interventional procedures by collecting anonymized patient data from multiple US clinical institutions.
|
|
Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (EGGMIO RGN)
|
Research Initiative
|
HRSA
|
NHGRI
|
The purpose of this Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Network (EGGMIO-RGN) project is to evaluate the implementation and outcomes of selected RGN program activities aimed to improve access to services for individuals with, or at risk for, genetic or genomic conditions and their families, especially those among underserved populations. This evaluation will be used to inform the RGN recipients and the field of genetic and genomic medicine with best practices and strategies to implement genetic and genomic advances into clinical and public health.
|
|
Evaluation of Oropharyngeal responses to SARS-CoV-2
|
Research Initiative
|
FDA
|
NIAID
|
Evaluation of Oropharyngeal responses to SARS-CoV-2
|
|
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease
|
Research Initiative
|
FDA
|
NHLBI
|
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease
|